Authors

Streptococcus Pneumoniae Bacteremia Secondary to Community-Acquired Pneumonia: Another Case of Shorter Is Better?

Study questions whether reducing antibiotic treatment duration for pneumococcal bacteremia still ensures effective outcomes and minimizes risks.

The Promise of Lenacapavir in the Current Era

This newly approved long-acting injectable PrEP offers 6 months of HIV protection, and represents a major scientific and policy breakthrough. However, its success will depend on ensuring equitable access, enforcing coverage requirements, and maintaining a robust, multi-faceted HIV prevention infrastructure amid political and systemic challenges.

From Poultry to Public Health: Understanding the H5N1 Threat

Veterinary and public health officials share the important roles of surveillance and prevention strategies, insights on the virus's transmission pathways, historical context, the One Health approach, and highlights effective precautionary measures to mitigate H5N1 risks.

A Dose of Clarity: Low- vs High-Dose Trimethoprim-Sulfamethoxazole for Stenotrophomonas maltophilia Pneumonia

Findings from a recent study challenge the need for high-dose trimethoprim-sulfamethoxazole in managing Stenotrophomonas maltophilia pneumonia, finding lower doses may offer comparable efficacy.

The Changing Climate of Vector-Borne Diseases

These types of infections will continue to rise, and there is a need to understand what we are witnessing and find ways to combat them.

Precision in Practice: PK/PD Modeling Advances Infectious Disease Care

At MAD-ID, Marc Scheetz, PharmD, discusses how PK/PD modeling and AUC-based strategies offer safer, more precise antibiotic therapy.

Tuberculosis Meningitis in an Immunocompetent Patient

Read more about the case of a 71-year-old man who was admitted after presenting with cold-like symptoms for 3 weeks.

How Typhoid Fever Triggers Severe Neurological Symptoms

Yale researchers have discovered how typhoid fever triggers neurological symptoms, offering new insight into treatment options.

A No-Carb Diet: An Overview of Non–Carbapenemase-Producing Carbapenem-Resistant Enterobacterales

Non–carbapenemase-producing carbapenem-resistant Enterobacterales (CRE) isolates are the most common mechanism of CRE in the United States, but the optimal antimicrobial treatment remains to be elucidated.

STAY PrEPARED: Understanding COVID-19 Pre-Exposure Prophylaxis

New therapeutics offer some hope in this emerging market.

Protectors vs Police: How Antimicrobial Stewardship Interventions Come Across and How to Change the Narrative

How stewardship teams communicate determines whether interventions feel like policing or collaboration. Using structured, data-driven frameworks— advocacy-inquiry-listen-teach and DART—creates psychological safety to explore understanding and supports shared decision-making.

Unlocking New Defenses: The Changing Landscape of Candida auris Management

Candida auris is a highly drug-resistant, hospital-acquired fungal pathogen. With limited treatment options, here is an overview of some of the next-generation antifungals as well as combination therapeutics.

Using the NARROWS Framework to Improve Antibiotic Stewardship: A Communication Tool for Hospital Clinicians

The NARROWS framework, developed within the IDSA Core Antimicrobial Stewardship Curriculum, provides a structured, behaviorally informed approach to communication that helps stewardship teams address the social, emotional, and cultural factors influencing prescribing decisions in order to optimize antimicrobial use and combat resistance.

Bordetella bronchiseptica Clinical Application and Treatment Review

Bordetella bronchiseptica is a rare human respiratory pathogen that can be initially confused for Bordetella pertussis, leading to potentially inadequate treatment. This article reviews the organism and recent literature on the successful treatment of B bronchiseptica.

Tuberculosis Meningitis in an Immunocompetent Patient

Read more about the case of a 71-year-old man who was admitted after presenting with cold-like symptoms for 3 weeks.

Tuberculosis Meningitis in an Immunocompetent Patient

Read more about the case of a 71-year-old man who was admitted after presenting with cold-like symptoms for 3 weeks.

Daptomycin Resistance Among Enterococci Is a Growing Antimicrobial Resistance Threat

In a world heavily focused on therapeutic options for multidrug-resistant gram-negative organisms, the emergence of antimicrobial resistance among enterococci is often an under-recognized risk.

Measles: An Old Foe Has Returned

Texas is experiencing its largest measles outbreak in 30 years and the Centers for Disease Control and Prevention's (CDC) Epidemic Intelligence Service is providing support there. Here is an overview on testing, disease presentation, and vaccination, as well as commentary on the public health impact of vaccine hesitancy, and the unintended consequences of the immunization program’s success.

Daptomycin Resistance Among Enterococci Is a Growing Antimicrobial Resistance Threat

In a world heavily focused on therapeutic options for multidrug-resistant gram-negative organisms, the emergence of antimicrobial resistance among enterococci is often an under-recognized risk.

The Aminoglyco-Side Hustle: What’s Now and Next in Gram-Negative Infections

In the midst of many changes surrounding aminoglycosides over the past several years, clinicians may be left wondering if these agents still have a role in modern clinical practice. This article summarizes changes impacting aminoglycosides, discusses where these agents may still have a role in the context of gram-negative infections, and explores future areas of study.

Is Renal-Adjusted Ceftazidime/Avibactam in Patients With KPC-Producing Klebsiella Pneumoniae Bloodstream Infection Associated With Increased Mortality?

Can AI Solve the Skills Shortage in Antimicrobial Stewardship?

A recent literature review describes the current state of artificial intelligence tools for guiding antimicrobial therapy. Are you ready for change?

Dose Optimization as a Strategy to Improve Clinical Outcomes and Suppress Antimicrobial Resistance

From the discovery of penicillin to PK-PD principles: A brief historical overview and what we have learned from recent clinical trials.

COVID-19: The Gaps in Science Communication

The COVID-19 pandemic intensified long-standing problems in scientific production and communication—driven by perverse academic incentives, peer review strain, media hype, and growing misuse of AI—highlighting the urgent need for stronger critical appraisal skills across research and medicine.

Ocular Syphilis and Neurosyphilis in a Patient Living With HIV

Undermining HIV Prevention Now Will Cost Billions Later

The 15th anniversary of the Affordable Care Act is overshadowed by threats to HIV prevention efforts, including a looming Supreme Court case that could eliminate no-cost access to preexposure prophylaxis and other preventive services. Simultaneously, deep federal cuts and restructuring have destabilized critical public health infrastructure, jeopardizing decades of progress in the fight against HIV.

Follow the Science: Why CD4 Testing Is Critical in the Fight Against HIV/AIDS

To meet ambitious targets for ending the HIV/AIDS epidemic, governments must unite in a global effort to improve access to CD4 testing.

Protectors vs Police: How Antimicrobial Stewardship Interventions Come Across and How to Change the Narrative

How stewardship teams communicate determines whether interventions feel like policing or collaboration. Using structured, data-driven frameworks— advocacy-inquiry-listen-teach and DART—creates psychological safety to explore understanding and supports shared decision-making.

The Great Debate: To Extend or Not Extend?

A recent study examined how rurality and the availability of postdischarge follow-up influence clinicians’ decisions on antibiotic duration at discharge for patients hospitalized with community-acquired pneumonia.

What's New in 2025: From the CLSI Subcommittee on Antimicrobial Susceptibility Testing

The subcommittee approved the removal of doxycycline and tetracycline breakpoints, revised aminoglycoside breakpoints for Acinetobacter spp, and added aztreonam-avibactam breakpoints for Enterobacterales.